Drug Search Results
More Filters [+]

Foretinib

Alternative Names: foretinib, xl880, gsk1363089
Latest Update: 2023-10-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: RTK Inhibitor,C-Met Inhibitor,VEGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Foretinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Lung Cancer|Gastrointestinal Cancer|Renal Cell Carcinoma|Breast Cancer

Phase 1: Oncology Solid Tumor Unspecified|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IND197

P2

Completed

Breast Cancer

2014-12-14

I198

P2

Completed

Breast Cancer

2014-05-14

NCT02034097

P2

Withdrawn

Non-Small-Cell Lung Cancer

2014-04-01

I196

P2

Completed

Lung Cancer

2014-03-21

Recent News Events